Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial by Hussain, Syed A, Prof, Lester, Jason F, FRCR, Jackson, Richard, PhD, Gornall, Matthew, BSc, Qureshi, Muneeb, FRCR, Elliott, Anthony, PhD, Crabb, Simon J, PhD, Huddart, Robert A, Prof, Vasudev, Naveen, PhD, Birtle, Alison J, Prof, Worlding, Jane, FRCR, James, Nicholas D, Prof, Parikh, Omi, FRCR, Vilarino-Varela, Maria, FRCR, Alonzi, Roberto, MD, Linch, Mark D, PhD, Riaz, Irbaz B, MD, Catto, James W F, Prof, Powles, Thomas, Prof, Jones, Robert J, Prof

Get full text

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, plat... by James, Nicholas D, Prof, Sydes, Matthew R, MSc, Clarke, Noel W, Prof, Mason, Malcolm D, Prof, Dearnaley, David P, Prof, Spears, Melissa R, MSc, Ritchie, Alastair W S, MD, Parker, Christopher C, MD, Russell, J Martin, FRCR, Attard, Gerhardt, MD PhD, de Bono, Johann, Prof, Cross, William, PhD, Jones, Rob J, Prof, Thalmann, George, Prof, Amos, Claire, PhD, Matheson, David, PhD, Millman, Robin, Alzouebi, Mymoona, FRCR, Beesley, Sharon, FRCR, Birtle, Alison J, MD, Brock, Susannah, FRCR, Cathomas, Richard, MD, Chakraborti, Prabir, FRCR, Chowdhury, Simon, MD, Cook, Audrey, FRCR, Elliott, Tony, PhD, Gale, Joanna, DM, Gibbs, Stephanie, FRCR, Graham, John D, FRCP, Hetherington, John, FRCS[Eng], Hughes, Robert, FRCR, Laing, Robert, FRCR, McKinna, Fiona, FRCR, McLaren, Duncan B, FRCR, FRCP[Ed], O'Sullivan, Joe M, Prof, Parikh, Omi, FRCR, Peedell, Clive, FRCR, Protheroe, Andrew, PhD, Robinson, Angus J, FRCR, Srihari, Narayanan, MD, Srinivasan, Rajaguru, FRCR, Staffurth, John, MD, Sundar, Santhanam, FRCR, Tolan, Shaun, MD, Tsang, David, MCRP, Wagstaff, John, Prof, Parmar, Mahesh K B, Prof

Get full text

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial by Dearnaley, David, Prof, Syndikus, Isabel, MD, Mossop, Helen, MMathStat, Khoo, Vincent, MD, Birtle, Alison, FRCR, Bloomfield, David, FRCR, Graham, John, FRCR, Kirkbride, Peter, FRCR, Logue, John, FRCR, Malik, Zafar, FRCR, Money-Kyrle, Julian, FRCR, O'Sullivan, Joe M, Prof, Panades, Miguel, MRCR, Parker, Chris, FRCR, Patterson, Helen, FRCR, Scrase, Christopher, FRCR, Staffurth, John, MD, Stockdale, Andrew, FRCR, Tremlett, Jean, MSc, Bidmead, Margaret, MSc, Mayles, Helen, MSc, Naismith, Olivia, MSc, South, Chris, PhD, Gao, Annie, MSc, Cruickshank, Clare, BSc[Hons], Hassan, Shama, MSc, Pugh, Julia, CIM Dip, Griffin, Clare, MSc, Hall, Emma, PhD

Get full text

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial by Mateo, Joaquin, MD, Porta, Nuria, PhD, Bianchini, Diletta, MD, McGovern, Ursula, MD, Elliott, Tony, MD, Jones, Robert, Prof, Syndikus, Isabel, MD, Ralph, Christy, MD, Jain, Suneil, MD, Varughese, Mohini, FRCR, Parikh, Omi, FRCR, Crabb, Simon, MBBS, Robinson, Angus, FRCR, McLaren, Duncan, MBBS, Birtle, Alison, MD, Tanguay, Jacob, MBCHB, Miranda, Susana, BSc, Figueiredo, Ines, BSc, Seed, George, MSc, Bertan, Claudia, MSc, Flohr, Penny, BSc, Ebbs, Berni, BSc, Rescigno, Pasquale, MD, Fowler, Gemma, BSc, Ferreira, Ana, MSc, Riisnaes, Ruth, FIBMS, Pereira, Rita, BSc, Curcean, Andra, MD, Chandler, Robert, MD, Clarke, Matthew, BSc, Gurel, Bora, MD, Crespo, Mateus, MSc, Nava Rodrigues, Daniel, MD, Sandhu, Shahneen, MBBS, Espinasse, Aude, MSc, Chatfield, Peter, BSc, Tunariu, Nina, MD, Yuan, Wei, PhD, Hall, Emma, Prof, Carreira, Suzanne, PhD, de Bono, Johann S, Prof

Get full text

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind... by Tannock, Ian F, Prof, Fizazi, Karim, Prof, Ivanov, Sergey, MD, Karlsson, Camilla Thellenberg, MD, Fléchon, Aude, MD, Skoneczna, Iwona, MD, Orlandi, Francisco, MD, Gravis, Gwenaelle, MD, Matveev, Vsevolod, MD, Bavbek, Sevil, Prof, Gil, Thierry, MD, Viana, Luciano, MD, Arén, Osvaldo, MD, Karyakin, Oleg, Prof, Elliott, Tony, PhD, Birtle, Alison, MD, Magherini, Emmanuelle, MD, Hatteville, Laurence, MSc, Petrylak, Daniel, Prof, Tombal, Bertrand, Prof, Rosenthal, Mark, Prof

Get full text

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial by James, Nicholas D, Prof, Sydes, Matthew R, CSci, Mason, Malcolm D, Prof, Clarke, Noel W, Prof, Anderson, John, MD, Dearnaley, David P, Prof, Dwyer, John, FRIC, Jovic, Gordana, PhD, Ritchie, Alastair WS, FRCSEd, Russell, J Martin, FRCR, Sanders, Karen, BSc, Thalmann, George N, Prof, Bertelli, Gianfilippo, MD, Birtle, Alison J, FRCR, O'Sullivan, Joe M, Prof, Protheroe, Andrew, PhD, Sheehan, Denise, FRCR, Srihari, Narayanan, FRCR, Parmar, Mahesh KB, Prof

Get full text

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the... by Wilkins, Anna, FRCR, Mossop, Helen, MMathStat, Syndikus, Isabel, FRCR, Khoo, Vincent, MD, Bloomfield, David, FRCR, Parker, Chris, FRCR, Logue, John, FRCR, Scrase, Christopher, FRCR, Patterson, Helen, FRCR, Birtle, Alison, FRCR, Staffurth, John, MD, Malik, Zafar, FRCR, Panades, Miguel, MRCR, Eswar, Chinnamani, FRCR, Graham, John, FRCR, Russell, Martin, FRCR, Kirkbride, Peter, FRCR, O'Sullivan, Joe M, Prof, Gao, Annie, MSc, Cruickshank, Clare, BSc (Hons), Griffin, Clare, MSc, Dearnaley, David, Prof, Hall, Emma, Dr

Get full text